Coeptis Therapeutics, Inc.
NASDAQ:COEPBiotechnology
+$0.73 today
- Market cap
- $57.63M
- Beta
- -0.43
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$1.97
Volume 0.18M
Average 0.05M
COEP EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Coeptis Therapeutics, Inc.NASDAQ: COEP
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$3.51M, compared with -$3.04M a year earlier. Trailing-twelve-month EBITDA was -$10.87M.
Context
- EBITDA amounted to 763.9% of revenue in FY2025.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of $204.46K (+102.0%) for the fiscal year ending Dec 2026, a step up from the -11.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$3.51M-300.0% QoQ
- Last fiscal yearDec 2025
- -$10.41M-11.0% YoY
- LTMMar 2026
- -$10.87M-9.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -15.2% | +100.5% | +115.7 pp |
| 1 year | -11.0% | +102.0% | +113.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (10.41M) USD
- Year-over-year change
- -11.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.41M) | -11.0% |
| FY2024 | 2024-12-31 | (9.38M) | +53.4% |
| FY2023 | 2023-12-31 | (20.12M) | +44.6% |
| FY2022 | 2022-12-31 | (36.35M) | -183.7% |
| FY2021 | 2021-12-31 | (12.81M) | — |
EBITDA vs competitors
How COEP compares with its peers on the latest reported figures
- COEP's LTM Mar 2026 EBITDA of -$10.87M is the 2nd highest of the 9 companies compared; the peer median is -$29.02M.
- Its year-over-year change of -9.4% is the 4th highest of 9, against a peer median of -148.5%.
- EBITDA amounts to 769.0% of revenue for COEP, versus a peer median of 557.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$9.22M | +26.2% | — | — | |
| LTM Mar 2026 | -$10.87M | -9.4% | — | 769.0% | |
| LTM Mar 2026 | -$15.84M | +57.4% | — | 48.4% | |
| LTM Mar 2026 | -$18.95M | -40.5% | — | — | |
| LTM Mar 2026 | -$23.33M | -0.3% | — | 1017.5% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | -$34.71M | -256.5% | — | — |
| LTM Mar 2026 | -$62.08M | -482.8% | — | 18634.1% | |
| LTM Mar 2026 | -$89.9M | -1211.1% | — | — | |
| LTM Mar 2026 | -$147.92M | -653.3% | — | 97.9% | |
| Peer median (excluding COEP) | -$29.02M | -148.5% | — | 557.7% | |
Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 75K | 0 | 0 | 0 | 1.36M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 180.63K |
| Gross Profit | 75K | 0 | 0 | 0 | 1.18M |
| Gross Margin | 100.0% | — | — | — | 86.7% |
| Research & Development | 0 | 20.89K | 6.67M | 2.33M | 1.28M |
| Selling, General & Admin | 14.12M | 34.18M | 13.82M | 6.72M | 11.95M |
| Operating Expenses | 14.12M | 34.2M | 21.49M | 10.05M | 14.23M |
| Depreciation & Amortization | 447.41K | 1M | 1.04M | 1.04M | 1.22M |
| EBITDA | (12.81M) | (36.35M) | (20.12M) | (9.38M) | (10.41M) |
| EBITDA Margin | -17086.3% | — | — | — | -763.9% |
| Operating Income | (14.05M) | (34.2M) | (21.49M) | (10.05M) | (13.04M) |
| Operating Margin | -18727.9% | — | — | — | -956.9% |
| Interest Income | 0 | 0 | 0 | 0 | 116.5K |
| Interest Expense | 187.13K | 218.41K | 107.69K | 396.12K | 642.38K |
| Other Income / Expenses | 596.65K | (3.38M) | 224.59K | (822.92K) | 766.31K |
| Income Before Tax | (13.45M) | (37.57M) | (21.27M) | (10.88M) | (12.28M) |
| Pre-Tax Margin | -17932.4% | — | — | — | -900.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (13.45M) | (37.57M) | (21.27M) | (10.68M) | (11.92M) |
| Net Margin | -17932.4% | — | — | — | -874.3% |
| EPS (Basic) | (13.16) | (2.87) | (0.83) | (5.65) | (2.81) |
| EPS (Diluted) | (13.16) | (2.87) | (0.83) | (5.65) | (2.81) |
| Weighted Avg Shares | 1.02M | 14.3M | 25.69M | 1.93M | 4.23M |
| Weighted Avg Shares (Diluted) | 1.02M | 14.3M | 25.69M | 1.93M | 4.23M |
Coeptis Therapeutics, Inc.
NASDAQ:COEP
Intrinsic Alpha fair value
Locked
Current Price
$14.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.